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ABSTRACT
Serious bacterial infections are the single most important cause of neonatal mortality in developing coun-
tries. Case-fatality rates for neonatal sepsis in developing countries are high, partly because of inadequate 
administration of necessary antibiotics. For the treatment of neonatal sepsis in resource-poor, high-mor-
tality settings in developing countries where most neonatal deaths occur, simplified treatment regimens 
are needed. Recommended therapy for neonatal sepsis includes gentamicin, a parenteral aminoglycoside 
antibiotic, which has excellent activity against gram-negative bacteria, in combination with an antimicro-
bial with potent gram-positive activity. Traditionally, gentamicin has been administered 2-3 times daily. 
However, recent evidence suggests that extended-interval (i.e. >24 hours) dosing may be applicable to 
neonates. This review examines the available data from randomized and non-randomized studies of ex-
tended-interval dosing of gentamicin in neonates from both developed and developing countries. Avail-
able data on the use of gentamicin among neonates suggest that extended dosing intervals and higher 
doses (>4 mg/kg) confer a favourable pharmacokinetic profile, the potential for enhanced clinical efficacy 
and decreased toxicity at reduced cost. In conclusion, the following simplified weight-based dosing regi-
men for the treatment of serious neonatal infections in developing countries is recommended: 13.5 mg 
(absolute dose) every 24 hours for neonates of >2,500 g, 10 mg every 24 hours for neonates of 2,000-2,499 
g, and 10 mg every 48 hours for neonates of <2,000 g.
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INTRODUCTION
Global importance of neonatal infections
An estimated four million neonatal deaths occur 
around the world every year (1). Approximately 
99% of these deaths occur in developing countries 
(1-3). Serious bacterial infections are the single most 
important cause of morbidity and mortality among 
newborns (1,4-6). An estimated 20% of all children 
born in developing countries, or 30 million annu-
ally, develop an infection during the neonatal pe-
riod, and infectious diseases account for 36% of all 
neonatal deaths (1,7-9). Recent data suggest that 
approximately one-half of neonatal deaths in high-
mortality settings are due to infections (1,4,10). 
For the treatment of serious bacterial infections in 
neonates, the World Health Organization (WHO) 
recommends intramuscular injections of an ami-
noglycoside and penicillin antibiotics for at least 10 
days (11). The recommendations of WHO were de-
signed for infants aged seven days to two months 
and include gentamicin dosed at 7.5 mg/kg intra-
muscularly once daily (11). Gentamicin is a potent 
aminoglycoside antibiotic with bactericidal activity 
against gram-negative bacteria. The combination 
of gentamicin and a penicillin, such as ampicillin, 
also produces synergistic activity against several 
principal gram-positive pathogens in neonates. Darmstadt GL et al. Gentamicin dosing in neonates
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In addition to the use of gentamicin in combina-
tion with an injectable penicillin, alternative treat-
ment regimens, such as combining gentamicin 
with administration of oral antibiotics, including 
co-trimoxazole, may be life-saving (10). However, 
until further studies are available which provide 
evidence for efficacy of oral antibiotic treatment of 
neonates with suspected sepsis, or perhaps a subset 
with low-risk indications, every attempt should be 
made to provide a full course of parenteral antibiot-
ics. Thus, a primary variable in treatment regimens 
that may potentially be altered to simplify dosing 
is the duration of the interval between administra-
tions of doses.
The case-fatality rate due to neonatal sepsis in de-
veloping countries is estimated at 40%, based large-
ly on data for infants treated in hospitals (9,12). 
When neonatal infections occur, many deaths can 
be avoided if the signs are recognized early and the 
disease is treated promptly and adequately (3,13-
15).  In rural India and Bangladesh, for example, 66-
75% and 88-90% of births, respectively, take place 
at home, and acceptance of delivery in a health fa-
cility by rural women is still minimal (16-21).  Since 
signs of illness due to infections are most likely to 
manifest while the infant is at home, and families 
in many societies are reluctant to take newborns 
outside the home, even when they are ill (20), an 
important strategy for reducing neonatal mortality 
will be to improve the ability of caregivers in the 
family and community to recognize danger signs 
and to promptly seek care. The ability of first-line 
health workers to prevent, recognize, and provide 
initial case management of infectious diseases in 
the home and community, or at health facilities, 
will also need to be improved (10,22-24).  
For the treatment of neonatal sepsis in resource-
poor, high-mortality settings in developing coun-
tries where most neonatal deaths occur (1), simpli-
fied regimens are needed which ideally would allow 
for extended-interval dosing of parenteral antibio-
tics no more frequently than once a day. Although 
extended-interval dosing with parenteral antibio- 
tics is desirable in developed countries, it is essential 
in developing-country community settings. Home-
visits by community health workers to administer 
parenteral antibiotics, or alternatively, visits to the 
health facility by patients to receive injectable an-
tibiotics generally are not feasible more than once 
per day. Extended-interval dosing in health facili-
ties could also potentially reduce costs associated 
with antibiotic treatment, including demands on 
staff time, reduce demands on logistic and supply 
systems, and minimize chances for iatrogenic prob-
lems associated with antibiotic administration. 
In this article, we reviewed the safety and efficacy 
of extended-interval dosing of gentamicin and the 
implications for treatment strategies for neonatal 
sepsis in developing countries. We also recommend 
a feasible, simplified dosing strategy.
MATERIALS AND METHODS
We performed a MEDLINE/PubMed search for any 
published studies of extended-interval dosing of 
aminoglycoside in the literature in English. We used 
the following search strategies: (a) aminoglycoside 
and newborn and dosing, (b) gentamicin and new-
born and dosing, (c) treatment and newborn and 
sepsis, (d) aminoglycoside and dosing and sepsis, 
and (e) gentamicin and dosing and sepsis. This 
review includes all the relevant published stud-
ies that included information on aminoglycoside, 
specifically gentamicin, dose, dose interval, serum 
concentrations, efficacy, and signs of toxicity.
RESULTS
Gentamicin pharmacokinetic studies: overview
Intramuscular vs intravenous injection
Given the limited access that exists to the supplies 
and equipment needed to provide intravenous an-
tibiotic therapy in community-based settings and 
in many health facilities in developing countries, it 
is often necessary to administer antibiotics by the 
intramuscular route. Results of pharmacokinetic 
studies of aminoglycosides in general and gentami-
cin in particular have demonstrated that the serum 
concentration-time curves after an intramuscular 
injection and a 20- to 30-minute intravenous in-
fusion are nearly superimposable (25-34). The six-
hour serum concentrations, half-lives, and area-un-
der-the-curve values are also equivalent. Thus, data 
from studies that used intravenous administration 
can be extrapolated to settings, such as developing-
country peripheral health facility or community 
settings, where intravenous administration gener-
ally is not possible and where the drug often will be 
delivered by the intramuscular route.
Pharmacokinetic principles of extended- 
interval dosing 
Efficacy 
Previously, it was standard of care to deliver genta-
micin in multiple doses per day, but in recent years 
there has been a trend towards administration of 
higher doses at prolonged intervals. Changes in Darmstadt GL et al. Gentamicin dosing in neonates
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dosing towards once-daily administration of gen-
tamicin were first evaluated and are now widely 
implemented in the care of adult patients. Once-
daily dosing for neonatal patients is now also be-
ing recognized as having many potential benefits 
(Table 1). 
Higher doses given at extended intervals allow for 
more rapid achievement of sufficiently high peak 
levels of drug to kill susceptible pathogens, while 
allowing time in-between doses to reach sufficient-
ly low trough levels to avoid toxicity. Gentamicin 
exhibits a linear relationship between higher peak 
to minimum inhibitory concentration (MIC) ratio 
and improved clinical response. The post-antibio-
tic effect—or the ability of the drug to continue 
to suppress bacterial growth even after antibiotic 
concentrations have fallen below the MIC for the 
organism—of gentamicin is also concentration-de-
pendent (25,35). Moreover, adaptive resistance is 
thought to occur after continuous exposure of bac-
teria to antibiotic concentrations that are less than 
the MIC. 
Current research on administration of gentamicin 
in neonates further extends these principals to in-
clude even higher doses given at intervals longer 
than 24 hours, such as 36-48 hours (36,37). Since 
this approach to administration of gentamicin is 
relatively new, there are few safety data available 
in large numbers of patients, particularly neonates, 
and even fewer data from developing-country set-
tings in neonates who received higher doses at 
prolonged intervals; these data are reviewed below. 
Data are reviewed separately for neonates in de-
veloped-  and  developing-country  settings  due  to 
differences in various factors, including newborn 
care (e.g. fluid administration and monitoring and, 
thus, hydration status) and health status (e.g. sever-
ity of illness at the time of presentation due to de-
lays in seeking, reaching, and receiving appropriate 
care) (38). 
In adult patients, clinical outcome, including mor-
tality due to sepsis or pneumonia (39-42), was 
shown to depend principally on rapid achieve-
ment of therapeutic peak serum levels of drug on 
the first day of treatment. Mortality from sepsis or 
pneumonia dropped from 21% to 2.4% depend-
ing on whether or not serum gentamicin levels 
exceeded 5 µg/mL on the first day (40), and in an-
other study, cure rate from bacteraemia was 88% 
vs 12% depending on whether or not peak serum 
levels exceeded 5 or 8 µg/mL in patients with sep-
sis and pneumonia respectively within the first 
three days (39).
Toxicity
The principal adverse effects of gentamicin therapy 
are renal toxicity which nearly always is reversible 
and ototoxicity which generally is not reversible. 
Risk factors for aminoglycoside toxicity include 
baseline renal impairment, prolonged and repeat 
courses of administration of gentamicin, and in 
particular, prolonged serum concentrations above 
threshold levels, specifically prolonged high trough 
concentrations that exceed 2 µg/mL for longer 
than 10 days (25,43). The amount of drug that ac-
cumulates in sensitive organs, namely the kidney 
and inner ear, increases with higher plasma con-
centrations and longer periods of exposure. Elimi-
nation of drug from these organs, on the other 
hand, occurs more slowly than from plasma and 
is retarded by high plasma concentrations. Back 
diffusion from these sensitive organs to the blood, 
thereby lowering end-organ drug levels, is depen-
dent primarily on the trough rather than the peak 
concentration of drug in the serum. This accounts 
for the association between toxicity and high plas-
ma  trough  concentrations.  Once-daily  dosing 
or extended-interval dosing, despite the higher 
peak concentration, provides a longer period when 
con serum centrations are below the threshold for 
toxicity than do multiple-daily dosing regimens, 
leading to reduced risk for toxicity. 
Experience with once-daily dosing regimens strong-
ly suggests that high peak levels of 3 to 4-fold high-
Table 1. Advantages of once-daily and extended- 
                 interval gentamicin dosing regimens com- 
                pared to multiple-daily dosing regimens
Higher peak serum levels and higher peak 
level: MIC ratio
   Prolonged post-antibiotic effect (i.e. 
prolonged efficacy)
   Greater initial bacterial killing
      Reduced risk for emergence of resistant 
strains of bacteria
Sub-toxic drug trough levels maintained for 
longer periods
   Reduced risk for ototoxicity and 
nephrotoxicity
More cost-effective
   Reduced costs for supplies, preparation, and 
administration of drug
   Reduced costs for therapeutic drug 
monitoring
   Reduced costs for managing complications due 
to drug toxicity
MIC=Minimum inhibitory concentrationDarmstadt GL et al. Gentamicin dosing in neonates
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er than those achieved with multiple-daily dosing 
regimens, even in excess of 25 µg/mL, do not in-
crease toxicity (25,44-46). In adult patients, enough 
experience has accumulated with once-daily dos-
ing regimens that peak concentrations are no lon-
ger determined routinely. Prolonged dosing inter-
vals with higher doses of drug may minimize the 
risk of nephrotoxicity because renal cortical uptake 
of drug appears to be saturable, reaching a plateau 
despite increasing peak levels of drug. In general, 
results of studies in animal models have shown 
that administration of larger, less-frequent doses of 
aminoglycoside results in lower renal cortical con-
centrations of drug than found using lower-dose, 
multiple-daily dosing (47). Similarly, although the 
relationship between ototoxicity and aminoglyco-
side dosing regimen or threshold levels for toxici-
ty is less well-understood, available data suggest 
that once-daily dosing of aminoglycosides does 
not increase the risk of ototoxicity (48). Neonates, 
especially preterm and sick term infants, have low 
glomerular filtration rates which accounts for their 
slower clearance of medications, such as aminogly-
cosides (49,50). Therefore, extended-interval dos-
ing may be particularly advantageous in neonates 
by allowing for safer trough concentrations to be 
achieved.
Cost-savings
Extended-interval is a more cost-effective method 
for treating patients with gentamicin (Table 1) 
(51,52). There are fewer doses to prepare and ad-
minister per day than with multiple-daily dosing. 
Once-daily dosing saves costs of drug supply, phar-
macy and nursing personnel, and costs of thera-
peutic drug monitoring are reduced because fewer 
determinations of serum gentamicin concentra-
tions are necessary to monitor for ototoxicity and 
nephrotoxicity.
Summary of studies on extended-interval 
dosing in neonates
Several studies have been published on extended-
interval dosing of gentamicin in neonatal pa-
tients in both developed (20 studies, Table 2) and 
developing-country settings (8 studies, Table 3) 
(26,36,37,51,53-72,76-79). As noted above, we 
examined the pharmacokinetic parameters in these 
two groups of patients separately. Experts maintain 
that the trough levels should be <2 µg/mL (37,60,73), 
and some now recommend that the trough level 
should be <1 µg/mL (74). Most experts also recom- 
mend that the goal for peak serum levels in neo-
nates should be 5-12 µg/mL (37,60,73). Thus, the 
literature was reviewed with these target pa-
rameters in mind as a guide to appropriate dosing. 
We present information regarding procedures for 
monitoring of serum gentamicin concentration 
for each study included in this review whenever 
available (Table 2-3). Although monitoring of se-
rum creatinine levels and urine output to assess 
renal function and toxicity are recommended for 
patients receiving gentamicin therapy, procedures 
for such monitoring were not consistently or uni-
formly followed among the studies included in this 
review. Furthermore, as serum creatinine levels in 
neonates vary by gestational age, chronologic age, 
weight, and maternal renal function, interpreta-
tion of these values is complex. As such, we did not 
include data regarding serum creatinine levels, or 
potential renal toxicity in Table 2-3.
In 2006, a Cochrane review compared once-daily 
dosing with multiple-daily dosing of gentamicin 
regimens for the treatment of suspected or proved 
sepsis in preterm neonates (75). The authors in-
cluded 11 studies and 574 neonates >32 weeks 
gestation in which once-daily dosing (but not lon-
ger intervals) was compared with multiple-daily 
dosing regimens among newborns of ≤28 days 
and included two studies in which intramascular, 
in addition to intravenous, dosing was used. The 
studies reviewed reflected both developed (7 stud-
ies)- and developing (4 studies)-country settings. 
In this review, we included 16 additional studies 
in neonates from developed countries (36,37,54-
56,61,63-69,76-77) and four additional studies 
from developing countries (71,72,78,79), adding 
significantly to the evidence base for extended-in-
terval dosing. The Cochrane review cited reasons 
for excluding several studies included in this review 
as: use of a loading dose (72), non-randomized or 
quasi-randomized study design (36,61,63,68,79), 
or comparison of once-daily to longer-dosing 
intervals (37,77). Among the studies included in 
our review, two were published after the period of 
inclusion for the Cochrane review (71,76), three 
were purely descriptive studies (55,56,65), and five 
were studies in which either inconsistent dosing 
schedules were used in the control groups or the 
dosing regimens tested included ranges of dosing 
rather than a specific dose (54,64,66,67,69). We in-
cluded all these studies in this review to examine as 
much available evidence for the safety of extended-
interval dosing of gentamicin as possible.
The primary outcomes of the Cochrane review 
included clinical efficacy (clearance of sepsis) and 
pharmacokinetic efficacy (peak serum concentra-Darmstadt GL et al. Gentamicin dosing in neonates
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tions >5 µg/mL and trough concentrations <2 µg/
mL). Secondary outcomes included ototoxicity and 
nephrotoxicity. The authors concluded that the 
pharmacokinetic properties of once-daily dosing 
were superior to multiple-daily dosing regimens 
in that higher peak levels can be achieved while 
avoiding potentially toxic trough levels. They sug-
gested that further extending dosing intervals to 
36-48 hours might be appropriate. A recent meta-
analysis of aminoglycoside dosing in children that 
included 24 studies in patients aged up to 20 years 
(including 6 studies in neonates, 10 in developing 
countries) also reported that extended-interval dos-
ing provided similar efficacy and safety compared 
to multiple-daily dosing regimens (80). 
Developed-country studies
Dosing of 3-4 mg/kg 
In developed countries, in studies in which pa-
tients were given once-daily dosing of gentamicin 
at doses ranging from 3 to 4 mg/kg, trough levels 
almost uniformly were <2 µg/mL (Table 2). In seven 
studies, no patients had trough levels above 2 µg/
mL (51,54,57,60,61,63,77), and in other studies, 
5% (56), 18% (76), and 11% (55) of patients 
had  trough  levels  of  >2  µg/mL.  Bajaj  et  al.  per-
formed an observational study comparing stan-
dard-dose gentamicin (2.5 mg/kg administered 
every 12-24 hours) with an extended-interval dos-
ing  regimen  (4  mg/kg  administered  every  24-36 
hours) in 110 newborns with gestational ages 24-
40 weeks (69). They reported that similar numbers 
of patients had trough levels of <2 µg/mL for the 
standard  and  extended-interval  dosing  regimens 
(98% and 96.6% respectively), but a lower num-
ber of patients receiving extended-interval dosing 
compared to the standard-dose regimen had sub-
therapeutic peak levels of <5 µg/mL (20% and 92% 
respectively). Similarly, Hansen et al. measured se-
rum gentamicin concentrations in 214 newborns 
receiving once-daily dosing (3 mg/kg for patients 
<35  weeks  gestation  and  4  mg/kg  for  those  >35 
weeks) and reported that peak values of 6-12 µg/mL 
were achieved in 88% of patients and trough values 
of >2 µg/mL were noted in no patients studied (68). 
Other investigators have noted similar improved 
therapeutic levels in neonates with once-daily dos-
ing compared to multiple-daily dosing (66). 
Dosing >4 mg/kg
Published studies of particular interest for this review 
are those in which doses of >4 mg/kg were given 
by extended-interval dosing. Such dosing regimens 
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may be particularly applicable for use in developing 
countries, as this would create the possibility of giv-
ing the same dose at different intervals to neonates 
in different weight categories (e.g. a longer-dosing 
interval for patients of <2,000 g) while achieving 
therapeutic antibiotic serum levels. 
Hayani et al. compared twice-daily dosing of 2.5 
mg/kg gentamicin (n=15) with once-daily dosing 
of 5 mg/kg (n=11) in neonates >34 weeks gesta-
tion (range: 35-41 weeks) (26). All infants in the 
once-daily dosing group had therapeutic peak 
gentamicin concentrations while two patients in 
the twice-daily dosing group had sub-therapeutic 
peak concentrations <4 µg/mL. Seven patients had 
trough concentrations >2 µg/mL. One was a pre-
term infant in the once-daily dosing group, and six 
were term infants in the twice-daily dosing group. 
No nephrotoxic effects were observed. 
De Alba Romero et al. compared twice-daily dosing 
of 2.5 mg/kg of gentamicin (n=32) with once-daily 
dosing of 5 mg/kg/d (n=33) in infants of ≥1,200 g 
birthweight (53). Both premature and term infants 
were included in the study. All infants in the once-
daily dosing group had higher therapeutic peak 
concentrations (9.5 µg/mL±1.7 vs 6.4 µg/mL±1.6) 
and  lower  trough  concentrations  (1.4  µg/mL±0.7 
vs 2.2 µg/mL±1.0) than those in the control group. 
Only 3% of once-daily dosing patients—all preterm 
infants—had a high trough level; no term infants 
required the adjustment of dosage. There was no dif-
ference in clinical outcome between the two groups. 
In addition, once-daily dosing of gentamicin had 
practical advantages (less nursing time spent giving 
medication). The authors concluded that with once-
daily dosing, serum drug levels were more favour-
able for achieving both efficacy and reduced toxicity 
compared to twice-daily dosing.  
In another study, patients weighing 600-1,000 
g were given gentamicin of either 5 mg/kg every 
48 hours or 3 mg/kg every 24 hours while those 
weighing 1,001-1,500 g were given either 4.5 mg/
kg every 48 hours or 2.5 mg/kg every 24 hours (37). 
Trough concentrations were significantly lower in 
the higher dose, 48-hour interval dosing groups, 
and peak concentrations were in the therapeutic 
range significantly more often (90% v 55%). These 
authors suggested that the 48-hour dosing interval 
with the doses used might be too conservative and 
indicated that a shorter dosing interval of 36 hours 
might be optimal. These data suggest that, in very 
low-birthweight infants, extended-interval dosing 
may perform best if extended beyond 24 hours.  Darmstadt GL et al. Gentamicin dosing in neonates
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In a particularly instructive study by Stickland et al., 
modelling of gentamicin levels in neonates led to 
the development of the following optimized dos-
ing  schedule  that  then  was  tested  prospectively: 
neonates weighing >2,500 g received a dose of (5 x 
weight in kg) every 24 hours, and those weighing 
1,000-2,499 g received a dose of 1.5 x [(5 x weight)-
1] every 36 hours (36). Thus, for example, a baby 
weighing 1.5 kg received doses of 9.75 mg (6.5 
mg/kg) every 36 hours, and a baby weighing 2.0 
kg received doses of 13.5 mg (6.75 mg/kg) every 36 
hours. In this study, only one patient (2%) had a 
trough value of >2 µg/mL.
Tugay et al. evaluated the acute effects of extended-
interval dosing of gentamicin on glomerular and 
tubular renal functions among 61 preterm neo-
nates with suspected sepsis. A dose of 5 mg/kg was 
administered every 48 hours for patients ≤29 weeks 
gestational age, 4.5 mg/kg was administered every 
48 hours for patients 30-33 weeks gestational age, 
and 4 mg/kg was administered every 36 hours for 
patients 34-37 weeks gestation (76). Serum peak 
and trough levels, serum and urine creatinine, 
sodium and potassium levels, and urine albumin 
and calcium levels were measured at baseline, after 
the third dose of gentamicin, and at 48-72 hours 
after completion of gentamicin therapy. Overall, 
high trough (≥2 mg/L) and peak (≥9.99 mg/L) lev-
els were found in 5 (8.1%) and 11 (18%) neonates 
respectively. Additionally, 11 (18%) patients had 
sub-therapeutic peak levels (<6.1 mg/L). Of note, 
none of the neonates included in this study had 
proven sepsis during the study period. Although 
the authors reported weak but positive correlations 
between trough and peak gentamicin levels with 
serum creatinine, urine albumin/creatinine ratio, 
fractional excretion of potassium, fractional excre-
tion of sodium, and urinary calcium/creatinine 
ratios, pretreatment, treatment, and post-treat-
ment serum creatinine and fractional excretion of 
potassium values did not show any statistically sig-
nificant difference for sub-therapeutic (peak <6.1 
mg/L), therapeutic (trough <2 mg/L, peak 6.1-9.99 
mg/L) and high (trough >2 mg/L, peak >9.99 mg/L) 
trough and peak gentamicin levels. These data sug-
gest that the extended-interval regimens were safe.
Unpublished data 
In addition to published data, a co-author (MMB) 
of this review conducted a study in 1999 of 
once-daily dosing of gentamicin for neonates 
in the Neonatal Intensive Care Unit (NICU) at 
Duke University Hospital. The once-daily dosing 
protocol implemented for patients without renal 
dysfunction was as follows: infants <29 weeks ges-
tation received 3.5-4 mg/kg/dose every 48 hours, 
and infants >30 weeks gestation received 3.5-4 
mg/kg/dose every 24 hours. Renal dysfunction 
was defined as serum creatinine of >1.7 µg/mL. Pa-
tients with renal dysfunction were given 2.5 mg/kg 
of gentamicin for one dose, and a pharmacy con-
sultant provided recommendations for further 
dosing based on evaluation of pharmacokinetic 
parameters.
During the study period, gentamicin levels were 
not monitored for patients who received therapy 
for ≤48 hours. If the decision was made to continue 
therapy beyond 48 hours, gentamicin levels were 
monitored around the second dose for patients re-
ceiving gentamicin every 48 hours and around the 
third dose for patients receiving gentamicin every 
24 hours. The goal of therapy was a trough level of 
<1.5 µg/mL and a peak level of 5-10 µg/mL. In to-
tal, 244 courses of gentamicin therapy were admin-
istered during the study period. With these dosage 
and patient-management regimens, adjustment 
of dosage was required for 26 (10.7%) of the 244 
courses of therapy. Potentially toxic drug levels (i.e. 
trough >2 µg/mL or peak >10 µg/mL) were found 
in 12 (5%) cases. Based on these results, the once-
daily dosing gentamicin protocol has been used in 
the NICU at Duke University since the trial, with 
good results.
Developing-country studies
Studies on extended-interval dosing among neo-
nates in developing countries are summarized 
in Table 3. We evaluated these studies separately, 
given the higher rates of low birthweight and mal-
nutrition and the greater likelihood of sub-thera-
peutic hydration status of infants in these settings. 
Moreover, the focus of this review was to identify 
optimal extended-interval dosing regimens for in-
fants in low-resource settings. Although these dif-
ferences between settings could potentially result 
in differing pharmacokinetic profiles among target 
populations, at this time there are insufficient data 
to explore this specific question. 
In India, once-daily dosing of preterm infants be-
tween 32-36 weeks gestational age with 4 mg/kg  of 
gentamicin (n=9 patients) was compared with 
twice-daily dosing with 2.5 mg/kg/dose (n=9 pa-
tients) (58). Therapeutic peak levels of gentamicin 
after  the  first  dose  were  achieved  only  with  the 
once-daily dosing regimen, and the mean peak lev-
els at steady state were not significantly different 
for the two regimens. Patients who received 4 mg/
kg once daily had a mean trough level of 1.96±0.60 Darmstadt GL et al. Gentamicin dosing in neonates
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µg/mL, whereas those who received the twice-dai-
ly dosing regimen had trough levels of 2.76±0.70 
(p=0.019). It was concluded that once-daily dosing 
of gentamicin in preterm infants (32-36 weeks) pro-
vides initial peak serum concentrations above the 
MIC of gram-negative bacteria and trough concen-
trations below potentially toxic levels. Further, the 
recommendation was made to switch to once-daily 
dosing due to its monetary, logistical and pharma-
cokinetic advantages over twice-daily dosing.
In another study conducted in India, 73 newborns 
were stratified by gestational age (32-36 weeks ges-
tational age, and term infants) and randomized to 
receive either once-daily dosing (n=37) of 4 mg/kg 
or twice-daily dosing (n=36) of 2.5 mg/kg/dose 
(59). The authors reported that both mean peak 
and trough concentrations were similar for the two 
study groups, and they concluded that once-daily 
dosing was as effective as twice-daily dosing and 
was more cost-effective.   
In Thailand, Chotigeat et al. treated 54 infants of 
>2,000 g and ≥34 weeks gestational age, within the 
first seven days of life, with gentamicin given by 
either once-daily dosing (4-5 mg/kg) or multiple-
daily dosing (2-2.5 mg/kg every 12 hours) (62). The 
authors reported that, while three patients in the 
multiple-daily dosing group had peak or trough 
levels outside the acceptable ranges of peak 4-12 
µg/mL, trough <2 µg/mL, all patients in the once-
daily dosing group had acceptable peak and trough 
values. In an additional study in Thailand, 36 
newborns received either once-daily dosing (5 mg/
kg) or twice-daily dosing (2.5 mg/kg) of gentami-
cin; once-daily dosing resulted in a lower propor-
tion of patients with potentially toxic trough levels 
of >2 µg/mL compared to twice-daily dosing (22% 
vs 68% respectively), while the proportion of pa-
tients with therapeutic peak levels of >4 was similar 
between the two groups (100% and 96% respec-
tively) (70). Kiatchoosakum et al. administered 
gentamicin by once-daily dosing (4 mg/kg) to 105 
neonates in Thailand who were ≥2,000 g and ≥34 
weeks gestational age; 97% had peak levels of >4 
µg/mL, and 93% had trough levels of <2 µg/mL 
(71). No abnormal hearing test results (audiometry) 
were observed among 100 of these patients prior to 
discharge, and none of the 47 patients had abnor-
mal brainstem auditory evoked potentials at a six-
month follow-up visit. They reported no instances 
of nephrotoxicity. 
In Kenya, English et al. conducted a study compar-
ing once-daily dosing (2-6 mg/kg) after an 8-mg/kg 
loading dose with multiple-daily dosing (2.5 mg/kg 
given 2-3 times daily) of gentamicin (72). In this 
study, gentamicin was routinely administered as 
an intramascular injection. The authors reported 
that the serum trough concentrations were poten-
tially toxic (≥2 µg/mL) in 6% and 24% of patients 
receiving once-daily dosing and multiple-daily dos-
ing respectively, suggesting that once-daily dosing 
was safer than multiple-daily dosing. Peak serum 
gentamicin concentrations were potentially sub-
therapeutic (<4 µg/mL) in 12% and 19% of patients 
receiving once-daily dosing and multiple-daily dos-
ing respectively. 
In a study of extended-interval dosing of gentami-
cin  among  neonates  hospitalized  for  suspected 
sepsis in India and Bangladesh, Darmstadt et al. 
reported on the pharmacokinetics of a simplified 
weight-based gentamicin dosing regimen (78). In 
total, 110 patients whose birthweights were ≤3,000 
g were included in this study. The dose of gentami-
cin  administered  intravenously  varied  by  birth-
weight  category:  10  mg  (absolute  dose,  not  mg/
kg) every 48 hours for neonates of <2,000 g; 10 mg 
every 24 hours for neonates of 2,000-2,249 g; and 
13.5 mg every 24 hours for neonates of >2,500 g. 
The authors found that pharmacokinetic parame-
ters, i.e. elimination rate constant, serum half-life, 
and volume of distribution were similar among 
patients from both centres. Only one patient had 
a peak concentration <4 µg/mL, and 20% of pa-
tients had peak concentrations >10 µg/mL. 12.7% 
of patients had a trough gentamicin concentration 
>2 µg/mL. However, no patients with high trough 
and/or peak values showed a significant increase 
in serum creatinine. In total, 76 patients had hear-
ing testing performed at follow-up, of which only 
two had abnormal findings, but neither of these 
patients had elevated gentamicin peak or trough 
concentrations. The authors concluded that their 
extended-interval dosing regimen can be used safely 
and effectively in the treatment of neonatal sepsis 
in low-resource settings.  
Of the studies included in this review, information 
regarding potential ototoxicity with extended-in-
terval  dosing  of  gentamicin  regimens  was  avail-
able for 10 studies (37,51,53,60,63,65,71,75,77,78). 
Although none of these studies was powered to 
demonstrate a significant difference with respect to 
hearing loss, the results of these studies suggest that 
there was no appreciable difference in ototoxicity 
between neonates receiving extended-interval dos-
ing compared to multiple-daily dosing regimens of 
gentamicin (Table 2-3).
DISCUSSION
Review of available data suggests that gentamicin 
therapy in neonates in developed- and developing-Darmstadt GL et al. Gentamicin dosing in neonates
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country studies using extended-interval dosing 
with intervals of >24 hours and doses of >4 mg/
kg has reduced potential for toxicity while confer-
ring equal or greater clinical efficacy; therefore, its 
use, in combination with a penicillin derivative for 
gram-positive coverage, is growing as the standard 
for treatment of neonates in both developed and 
developing countries (25,48,81). None of the clini-
cal studies included in this review was powered in-
dividually to show a statistically significant differ-
ence in clinically-relevant outcomes of treatment 
success such as microbiological cure or decreased 
mortality; rather, the experimental designs rely on 
the assumption that the surrogate endpoint of gen-
tamicin peak serum concentration accurately re-
flects these outcomes. However, given that pooled 
data, such as those presented in the Cochrane Re-
view, suggest equivalence between extended-in-
terval dosing and multiple-daily dosing regimens, 
these studies provide important evidence suggest-
ing therapeutic efficacy of extended-interval dosing 
that extends to developing-country settings (75). 
We found no apparent differences in pharmacoki-
netics of gentamicin in developed-country settings 
compared to developing-country settings; howev-
er, further analyses are warranted as additional data 
become available.
While extended-interval dosing does not appear to 
increase nephrotoxicity or ototoxicity, these out-
comes have not been systematically or consistently 
evaluated in the studies of extended-interval dos-
ing with gentamicin among neonates. Extended-
interval dosing is potentially more cost-effective for 
treating neonatal patients with gentamicin, result-
ing in decreased time for the pharmacy and nursing 
staff, fewer administered doses per day, decreased 
costs of drug supply, and reduced costs of therapeu-
tic drug monitoring. Furthermore, it is possible that 
extended-interval dosing is less anxiety-provoking 
than multiple-daily dosing to patients and their 
families. This may, in fact, lead to improved accept-
ability of treatment and adherence to treatment in 
these settings as was observed in a recent study of 
hospital-based treatment of pneumonia in children 
comparing intramuscular once-daily dosing with 
multiple-daily dosing of gentamicin from Bangla-
desh (82). Based on the findings of this review, the 
development of optimal extended-interval dosing 
regimens for use in developing countries should be 
a research priority.  
Most hospitals in developing countries do not have 
the capacity to perform therapeutic drug monitor-
ing for gentamicin. Moreover, in settings where 
monitoring is available, the associated costs may 
be prohibitively high. Where gestational age is not 
consistently and reliably available, weight-based al-
gorithms may be of particular benefit. Treatment 
regimens could be simplified to include a limited 
selection of dosages (i.e. likely no more than two) 
but varying intervals based on weight. The dose in 
mg/kg that would be administered to newborns of 
various weights with two different unit doses (10 mg 
and 13.5 mg) is illustrated in the Figure. The 
weight range illustrated represents birthweights 
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obtained from a rural North Indian cohort which 
ranged from 2,000 g (5th percentile) to 3,500 g (95th 
percentile) (83). For patients in the 2,000-2,499 g 
strata, for example, the dosage administered would 
vary from 4 to 5 mg/kg. Results of our review sug-
gest that a 10-mg dose could be administered safely 
and effectively at two different intervals, i.e. every 
24 hours or every 48 hours, to neonates in two dif-
ferent, corresponding weight categories, e.g. 2,000-
2,499 g and <2,000 g respectively. Unit doses could 
potentially be prepared, for example, in pre-filled 
syringes, such as the Uniject™ (84) device, further 
reducing the risk of medication-administration er-
rors, enhancing ease of use (potentially even by 
community-based health workers), and potential-
ly creating a more favourable cost-benefit profile. 
Through such a simplified dosing scheme, it is con-
ceivable that, in some settings where facility-based 
or clinic-based care is unavailable or inaccessible, 
but where community case management of seri-
ous infections exists, doses could be administered 
in the home, where the majority of births in many 
low-resource settings occur, at the earliest possible 
point in the presentation of clinical sepsis. By treat-
ing uncomplicated cases of presumed neonatal 
sepsis in the home or at community-based clin-Darmstadt GL et al. Gentamicin dosing in neonates
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ics, the potential burden to the family of accessing 
hospital care and the costs associated with hospi-
talizations could also be alleviated. However, even 
in developing-country settings where home-based 
or clinic-based management of serious infections 
with parenteral antibiotics is not acceptable or fea-
sible, such an approach could facilitate life-saving 
treatment in health facilities at various levels of the 
health system, extending from peripheral, primary-
care centres to referral hospitals. Further research is 
needed to explore these potential applications of 
extended-interval dosing for gentamicin in various 
developing-country settings.
In summary, extended-interval dosing of gentami-
cin provides for a more favourable pharmacokinetic 
profile the multiple-daily dosing, the potential for 
enhanced clinical efficacy, reduced risk for emer-
gence of resistance organisms, and decreased toxic-
ity at reduced cost. Although data are limited on an-
ticipated effects of once-daily doses of gentamicin 
in the range of 5 mg/kg, it appears that the risk of a 
5-mg/kg dose is comparable with that for a 4-mg/kg 
dose. Based on the findings of this review, with the 
aim of developing a simple extended-interval dos-
ing regimen for use of gentamicin in neonates in 
developing-country settings with presumed sepsis 
or culture-proven sepsis with a gentamicin-suscep-
tible pathogen, we propose the following dosing 
regimen (absolute doses, not mg/kg): 
•	 13.5 mg every 24 hours for neonates of >2,500 g
•	 10 mg every 24 hours for neonates of 2,000-
2,499 g
•	 10 mg every 48 hours for neonates of <2,000 g
This dosage schedule has been successfully imple-
mented in a prospective study of hospitalized neo-
nates in Bangladesh and India (78). 
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